Biotech Sector Faces Workforce Cuts Amid FDA Approvals
Biotech firms restructure with layoffs as FDA approves new drugs, exemplifying industry challenges and opportunities.
- Latest
- Trending
Biotech firms restructure with layoffs as FDA approves new drugs, exemplifying industry challenges and opportunities.
Adaptimmune's Tecelra launch marks progress in cell therapy, with strong Q2 financials and strategic plans for cancer treatment.
Kezar halts tumor drug trials, pivots to autoimmune hepatitis focus with promising zetomipzomib.
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
Legend Biotech reports significant revenue growth in Q2 2024, with strategic advancements in CAR-T therapies.
Personalis sees 35% Q2 revenue growth, lifts full-year outlook to $79-$81M.
Explore top biotech stocks poised for growth amid market challenges. Learn about innovations and opportunities in gene therapy.
Nevro Corp. Q2 2024 revenue fell 4.3% due to competitive pressures. The company is exploring strategic options for growth.
Talkspace sees 29% revenue rise in Q2 2024 through new military contracts and expanded Medicare coverage.
Inspire Medical Systems reports a 30% revenue increase in Q2 2024, with net income of $9.8 million, and raises full-year ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.